Literature DB >> 22826484

Artesunate for severe acute Plasmodium falciparum infection in a patient with myasthenia gravis.

Nathalie Dournon1, Pierre Buffet, Eric Caumes, Bernard Clair, Stéphane Jauréguiberry.   

Abstract

We report a case of severe malaria in a patient with underlying myasthenia gravis who was successfully treated with artesunate. The outcome was favorable. Artesunate seems to be a good option for patients with underlying myasthenia gravis disease because they benefit from a better toxicity profile than quinine.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22826484      PMCID： PMC3435344          DOI： 10.4269/ajtmh.2012.12-0114

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  7 in total

1.  Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.

Authors:  R S Bedlack; D L Simel; H Bosworth; G Samsa; B Tucker-Lipscomb; D B Sanders
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

Review 2.  Quinine toxicity.

Authors:  D N Bateman; E H Dyson
Journal:  Adverse Drug React Acute Poisoning Rev       Date:  1986

3.  Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.

Authors:  Arjen Dondorp; François Nosten; Kasia Stepniewska; Nick Day; Nick White
Journal:  Lancet       Date:  2005 Aug 27-Sep 2       Impact factor: 79.321

4.  Myasthenia and malaria medicines.

Authors:  Philip R Fischer; Eric Walker
Journal:  J Travel Med       Date:  2002 Sep-Oct       Impact factor: 8.490

5.  Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand.

Authors:  J Karbwang; T Tin; W Rimchala; K Sukontason; V Namsiripongpun; A Thanavibul; K Na-Bangchang; P Laothavorn; D Bunnag; T Harinasuta
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Nov-Dec       Impact factor: 2.184

Review 6.  Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction.

Authors:  W Robberecht; J Bednarik; P Bourgeois; J van Hees; H Carton
Journal:  Arch Neurol       Date:  1989-04

7.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321
  7 in total
  2 in total

1.  Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013.

Authors:  Stéphane Jauréguiberry; Marc Thellier; Papa Alioune Ndour; Flavie Ader; Camille Roussel; Romain Sonneville; Julien Mayaux; Sophie Matheron; Adela Angoulvant; Benjamin Wyplosz; Christophe Rapp; Thierry Pistone; Bénédicte Lebrun-Vignes; Eric Kendjo; Martin Danis; Sandrine Houzé; François Bricaire; Dominique Mazier; Pierre Buffet; Eric Caumes
Journal:  Emerg Infect Dis       Date:  2015-05       Impact factor: 6.883

Review 2.  Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective.

Authors:  Alvin Pumelele Ndondo; Brian Eley; Jo Madeleine Wilmshurst; Angelina Kakooza-Mwesige; Maria Pia Giannoccaro; Hugh J Willison; Pedro M Rodríguez Cruz; Jeannine M Heckmann; Kathleen Bateman; Angela Vincent
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.